Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 18/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.80 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.50 |
| ▸ | SCD | O00767 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8312576 | 0.93 | MMP13 (1.00) | MMP13SLC22A8PTGER4 | |
| SCHEMBL6272431 | 0.91 | MMP13 (1.00) | MMP13SLC22A8PTGER4 | |
| SCHEMBL6270131 | 0.91 | MMP13 (1.00) | MMP13SLC22A8 | |
| SCHEMBL6272899 | 0.91 | MMP13 (1.00) | MMP13SLC22A8PTGER4 | |
| SCHEMBL6273558 | 0.90 | MMP13 (0.83) | MMP13SLC22A8PTGER4 | |
| SCHEMBL6363976 | 0.89 | MMP13 (1.00) | MMP13SLC22A8PTGER4 | |
| SCHEMBL6288857 | 0.89 | MMP13 (1.00) | MMP13SLC22A8 | |
| SCHEMBL6273591 | 0.89 | MMP13 (1.00) | MMP13SLC22A8PTGER4 | |
| Hydrochloric Acid SCHEMBL6359859 | 0.88 | MMP13 (0.98) | MMP13SLC22A8PTGER4 | |
| SCHEMBL6273019 | 0.87 | MMP13 (0.84) | MMP13SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005106495-A1 | PROCOLLAGEN II BIOMARKERS AND METHODS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-11-10 | — | — | WO | claimed |
| WO-2005106495-A1 | PROCOLLAGEN II BIOMARKERS AND METHODS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050085447-A1 | Pyrido[3,4-d]pyrimidine derivatives as matrix metalloproteinase-13 inhibitors | WARNER-LAMBERT COMPANY LLC | 2005-04-21 | — | — | US | disclosed |
| WO-2005016926-A1 | PYRIDO [3,4-D] PYRIMIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085447-A1 | Pyrido[3,4-d]pyrimidine derivatives as matrix metalloproteinase-13 inhibitors | MMP13, MMP9, MMP3 | MMP13 1/4885SLC22A8 2982/4885PTGER4 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.